Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22659058 | 0.88 | NCF1 (0.55) | NCF1HTTMAPTMAPK1AHR | |
| SCHEMBL29472100 | 0.86 | NCF1 (0.76) | NCF1HTTALDH1A1ADRB2PKM | |
| SCHEMBL22715673 | 0.86 | NCF1 (0.76) | NCF1HTTALDH1A1ADRB2PKM | |
| SCHEMBL731691 | 0.85 | NCF1 (0.74) | NCF1HTTMAPTPIK3CANPC1 | |
| SCHEMBL30734145 | 0.83 | NCF1 (0.67) | NCF1HTTMAPTMAPK1AHR | |
| SCHEMBL16549300 | 0.82 | GAA (0.53) | NCF1MAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3847734 | 0.82 | NCF1 (0.70) | NCF1HTTALDH1A1ADRB2PKM | |
| SCHEMBL3849006 | 0.82 | NCF1 (1.00) | NCF1HTTADRB2 | |
| SCHEMBL21190487 | 0.80 | NCF1 (0.67) | NCF1HTTIRAK4ALDH1A1ADRB2 | |
| SCHEMBL17579037 | 0.79 | MAPT (0.50) | NCF1HTTMAPTMAPK1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4183786-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-4183786-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| EP-3558321-B1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3558321-B1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| CN-101023080-A | Thiazolinone 4-monosubstituted quinolines | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | CN | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | NCF1 374/4885HTT 2757/4885MAPT 4203/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | NCF1 374/4885HTT 2757/4885MAPT 4203/4885 |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | NCF1 2427/4885HTT 3939/4885MAPT 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.